A股異動 | ST宇順(002289.SZ)復牌一字漲停 擬購買前海首科100%股權
格隆匯2月4日丨ST宇順(002289.SZ)復牌一字漲停,報8.1元,買一封單近2萬手,最新總市值22.7億元。ST宇順(002289.SZ)披露發行股份及支付現金購買資產並募集配套資金暨關聯交易預案,公司擬以發行股份及支付現金的方式,向凱旋門控股、白宜平購買其持有前海首科100%股權,此次交易完成後,前海首科將成為上市公司全資子公司。前海首科主要業務係為客户提供電子元器件產品分銷、技術支持及倉儲物流服務的整體解決方案。此次交易後,上市公司的資產質量及盈利能力都將得到明顯提升,抗風險能力和可持續發展能力得以增強。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.